Editor: Atta-ur-Rahman

Frontiers in Clinical Drug Research - Alzheimer Disorders

Volume 4

eBook: US $129 Special Offer (PDF + Printed Copy): US $219
Printed Copy: US $155
Library License: US $516
ISSN: 2451-8743 (Print)
ISSN: 2214-5168 (Online)
ISBN: 978-1-68108-148-9 (Print)
ISBN: 978-1-68108-147-2 (Online)
Year of Publication: 2015
DOI: 10.2174/97816810814721150401


Frontiers in Clinical Drug Research - Alzheimer Disorders is an e-Book series concerned with Alzheimer's disease (AD) that causes dementia, or loss of brain function. The disease affects the parts of the brain that deal with memory, thought, and language. Chapters in each volume focus on (Alzheimer Disorders) drug research with special emphasis on clinical trials, research on drugs in advanced stages of development and cure for Alzheimer’s disease and related disorders.

Frontiers in Clinical Drug Research - Alzheimer Disorders will be of particular interest to readers interested in drug therapy of this specific neurodegenerative condition and related brain disorders as the series provides relevant reviews written by experts in field of Alzheimer’s Disease research.

The fourth volume of this series features research on

- Melatoninergic Pathways in Alzheimer's disease,

- Nutritional Approaches in Alzheimer’s disease prevention,

- Updates on drugs and strategies for Alzheimer’s disease prevention


Alzheimer’s disease (AD) is the most common age-related multifactorial neurodegenerative disease which is described as the failure of cognitive performance and behavioral capabilities. The clinical features of Alzheimer’s disease (AD) are worsening cognition with progressive discrepancy in recovery of memory. The book series, “Frontiers in Clinical Drug Research – Alzheimer Disorders”, is intended to present the most important advancements in the field in the form of cutting edge reviews written by experts in this field of research. Volume 4 of this eBook series is a compilation of five well written chapters contributed by prominent researchers which include topics such as, the role of melatoninergic pathways, investigational drugs and nutritional approaches in the prevention and treatment of Alzheimer’s disease.

Anderson and Maes in Chapter 1 review the role of melatoninergic pathways in Alzheimer's disease. They also discuss the influence of primary and secondary sites of infection in the etiology and course of AD. In chapter 2, they describe the role of melatonin in more detail with respect to the changes and interventions relevant to AD.

Many researchers are aiming at understanding, preventing and curing AD. Several strategies are being studied for developing therapies against this disorder. Esiri and Wilcock, in Chapter 3 discuss the various approaches for the treatment and prevention of Alzheimer’s disease. This review also describes the primary and secondary prevention of AD and the links with cardiovascular disease, diet and other lifestyle-related risks.

Neuritic plaques containing β-amyloid and neurofibrillary tangles containing tau are the two key targets of drugs under investigation that could prevent or slow down the progress of Alzheimer’s disease. Pamela E. Potter, in Chapter 4, comprehensively explains the mechanism of action and results of clinical trials for the drugs that have been recently used or that are in development for the treatment and management of Alzheimer’s disease.

The role of adequate nutrition in the management of mild cognitive impairment (MCI) and Alzheimer's disease (AD) is extensively reviewed in Chapter 5 by Chen et al. This review also discusses the role of several natural products including micronutrients in the nutritional prevention of AD.

The 4th volume of the book series presents important recent researches that have been reviewed comprehensively by eminent researchers. I wish to express my gratitude to the contributors as well as the editorial staff, particularly Mr. Mahmood Alam (Director Publication), Mr. Shehzad Naqvi (Senior Manager Publications) and Ms. Fariya Zulfiqar (Assistant Manager Publications) for their hard work and persistent efforts.

Atta-ur-Rahman, FRS
Kings College
University of Cambridge


.Frontiers in Clinical Drug Research - CNS and Neurological Disorders.
.Frontiers in Clinical Drug Research - CNS and Neurological Disorders.
.Neurodegenerative Diseases: Multifactorial Degenerative Processes, Biomarkers and Therapeutic Approaches.
.Frontiers in Clinical Drug Research - CNS and Neurological Disorders.
.Traditional Medicine for Neuronal Health.
.Recent Advances in the Treatment of Neurodegenerative Disorders.
.Advances in Alzheimer Research.